13F Portfolios

RTW INVESTMENTS, LP — PTC THERAPEUTICS INC PTCT: Quarterly 13F Position History

RTW INVESTMENTS, LP has reported PTC THERAPEUTICS INC (PTCT) on 38 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2016. As of Q1 2026, the position is sized at 7,746,415 shares ($527.8M market value, 5.25% of the equity book).

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 38 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 7,746,415 0 $527.8M 5.25% $68.13
Q4 2025 7,746,415 0 $588.4M 5.89% $75.96
Q3 2025 7,746,415 0 $475.4M 5.86% $61.37
Q2 2025 7,746,415 +263,288 +3.5% $378.3M 5.39% $48.84
Q1 2025 7,483,127 +90,000 +1.2% $381.3M 5.83% $50.96
Q4 2024 7,393,127 0 $333.7M 5.05% $45.14
Q3 2024 7,393,127 0 $274.3M 3.97% $37.10
Q2 2024 7,393,127 30,843 -0.4% $226.1M 3.50% $30.58
Q1 2024 7,423,970 0 $216.0M 3.19% $29.09
Q4 2023 7,423,970 +188,774 +2.6% $204.6M 3.20% $27.56
Q3 2023 7,235,196 0 $162.1M 3.42% $22.41
Q2 2023 7,235,196 +141,898 +2.0% $294.3M 5.60% $40.67
Q1 2023 7,093,298 +1,477,911 +26.3% $343.6M 7.16% $48.44
Q4 2022 5,615,387 5,193 -0.1% $214.3M 4.38% $38.17
Q3 2022 5,620,580 +575,273 +11.4% $282.2M 6.50% $50.20
Q2 2022 5,045,307 175,921 -3.4% $202.1M 5.22% $40.06
Q1 2022 5,221,228 72,738 -1.4% $194.8M 4.03% $37.31
Q4 2021 5,293,966 0 $210.9M 3.08% $39.83
Q3 2021 5,293,966 0 $197.0M 2.97% $37.21
Q2 2021 5,293,966 0 $223.8M 3.38% $42.27
Q1 2021 5,293,966 +1,072,130 +25.4% $250.7M 3.91% $47.35
Q4 2020 4,221,836 +228,550 +5.7% $257.7M 4.32% $61.03
Q3 2020 3,993,286 +30,166 +0.8% $186.7M 4.49% $46.75
Q2 2020 3,963,120 +30,374 +0.8% $201.1M 5.66% $50.74
Q1 2020 3,932,746 +100,266 +2.6% $175.4M 7.55% $44.61
Q4 2019 3,832,480 +181,119 +5.0% $184.1M 7.00% $48.03
Q3 2019 3,651,361 +514,000 +16.4% $123.5M 7.34% $33.82
Q2 2019 3,137,361 +623,090 +24.8% $141.2M 7.54% $45.00
Q1 2019 2,514,271 +591,925 +30.8% $94.6M 6.46% $37.64
Q4 2018 1,922,346 1,353,245 -41.3% $66.0M 6.14% $34.32
Q3 2018 3,275,591 798,099 -19.6% $154.0M 9.22% $47.00
Q2 2018 4,073,690 64,270 -1.6% $137.4M 9.91% $33.73
Q1 2018 4,137,960 +7,845 +0.2% $112.0M 10.66% $27.06
Q4 2017 4,130,115 +634,972 +18.2% $68.9M 11.62% $16.68
Q3 2017 3,495,143 +190,929 +5.8% $69.9M 12.18% $20.01
Q2 2017 3,304,214 +1,998,571 +153.1% $60.6M 12.77% $18.33
Q1 2017 1,305,643 +308,477 +30.9% $12.8M 3.38% $9.84
Q4 2016 997,166 $10.9M 4.10% $10.91

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did RTW INVESTMENTS, LP first disclose a PTCT position in 13F-HR filings?

RTW INVESTMENTS, LP first reported PTC THERAPEUTICS INC (PTCT) on its 13F-HR filing for the period ending 2016-12-31 (Q4 2016). The position has appeared on 38 reported quarters within Pactolio's tracked window.

What was RTW INVESTMENTS, LP's most recent quarter-over-quarter share-count change in PTCT?

RTW INVESTMENTS, LP held the same 7,746,415 shares of PTCT between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent RTW INVESTMENTS, LP's cost basis in PTCT?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.